Severe maternal morbidity and prophylactic aspirin use
In Canada, the number of life-threatening health conditions during pregnancy, delivery and immediately after a delivery, has increased over time, affecting 14 per 1,000 deliveries. The most common severe maternal morbidities (SMM) are preeclampsia, cardiac conditions and severe blood loss.
Aspirin (ASA) has been shown to reduce the chance of developing preeclampsia when given before 20 weeks of pregnancy. However, the benefit of aspirin for SMM and other pregnancy complications is not clear.
This population-based cohort study of Canadian women examines:
- The risk of SMM and adverse pregnancy outcomes between users of low-dose ASA and non-users of ASA;
- The effects of ASA use and social inequities on SMM and adverse pregnancy outcomes; and
- The combined effect of ASA use and SARS-CoV-2 infection on SMM and adverse pregnancy outcomes.
Dr. Grandi is the Nominated Principal Investigator on this CIHR-funded project (PJT 186289).
Co-Principal Investigator: Dr. Joel Ray.
Treatment for subclinical hypothyroidism in pregnancy
Hypothyroidism is one of the most common endocrine disorders during pregnancy. It is characterized by an underactive thyroid and diagnosed based on high levels of thyroid stimulating hormone (TSH) with symptoms such as weight gain, fatigue and dry skin.
Subclinical hypothyroidism (SCH) occurs in 2.0–2.5% of pregnancies and is characterized by elevated TSH levels in the first trimester and normal thyroxine levels with no or mild symptoms of hypothyroidism.
The overall aim of this study is to determine if the use of levothyroxine (Synthroid®) during pregnancy is associated with the risk of adverse pregnancy outcomes and neurodevelopment outcomes in children born to women with SCH.
Dr. Grandi is a Co-Investigator and is co-lead of this CIHR-funded project with Principal Investigator Dr. Kristian Filion.
Pregnancy-related characteristics as risk factors for future risk of cardiovascular disease
Over the last decade, the incidence of serious maternal complications during pregnancy has steadily increased. These complications, including hypertensive disorders in pregnancy, gestational diabetes, preterm birth, stillbirth and placental abruption, are associated with an increased risk of poor maternal and fetal outcomes in pregnancy. These complications also contribute to adverse consequences for a woman’s longer-term health.
This study aims to develop and validate a risk prediction model to identify recently post-partum women at increased risk of developing cardiovascular disease (CVD) and cardiovascular risk factors immediately after an affected pregnancy.
Dr. Grandi is a Co-Investigator and co-lead of this CIHR-funded project with Principal Investigator: Dr. Kristian Filion.
Cardiovascular severe maternal morbidity and future cardiovascular risk
Despite improvements in maternal mortality, rates of severe maternal morbidity (SMM) have been steadily rising. A subset of these indicators, defined as cardiovascular SMM (CSSM), characterize cardiovascular complications during pregnancy. These indicators contribute to increased risk of maternal morbidity and mortality following an affected pregnancy.
Pre-eclampsia has been shown to increase the risk of long-term cardiovascular disease in women with an affected pregnancy. However, the contribution of CSMM to long-term cardiovascular risk in women with pre-eclampsia is unclear. Understanding how CSMM contributes to the long-term risk of cardiovascular disease can improve our ability to tailor prevention strategies for at-risk women.
The overall objective of this study is to examine the risk of cardiovascular disease, both overall and by subtypes, associated with CSMM among women with pre-eclampsia.
Dr. Grandi and Dr. Malhamé are Principal Investigators on this project.
The safety & effectiveness of biologics during pregnancy
Immune-mediated diseases, specifically autoimmune disorders (AID) and asthma, are highly prevalent in women of reproductive age and uncontrolled disease activity during pregnancy has been shown to negatively influence pregnancy, and maternal and child outcomes. Over the last decade, the use of biologic medications to treat AID and severe asthma has steadily risen due to its beneficial adverse effect profile. As pregnant women are typically excluded from RCTs, the safety and effectiveness of biologics in this group remains unknown. More importantly, there is a paucity of short- and long-term data on potential adverse outcomes in children exposed in utero to these medications.
Overarching goal and specific objectives
The main goal of this project is to conduct a BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with AID and asthma and their children (BIONIC). Specifically, in women who continue versus discontinue biologic use in pregnancy for AID and asthma, separately, we will compare the risks of:
- Adverse outcomes in infants (preterm birth, small-for-gestational age, major congenital malformations) and children (severe infections from 0 to 5 years old, type 1 diabetes, juvenile AID, asthma, atopic dermatitis)
- Adverse outcomes in mothers in pregnancy (hypertensive disorders of pregnancy, spontaneous and induced abortions, stillbirths, serious infections) and ≤1-year postpartum (serious infections)
- Maternal effectiveness outcomes (asthma and AID exacerbations in pregnancy)
Dr. Grandi and Dr. Longo are Principal Investigators on this project.
This project is funded by a grant from the CIHR’s Institute for Human Development, Child and Youth Health and a grant from the Canadian Foundation for Women’s Research.
Safe prescribing and use of medications
The Canadian Mother-Child Cohort Outreach (CAMCCO-Outreach) mission is to advocate for the safe prescribing and use of medications during pregnancy using real-world evidence, lived-experiences and community and partner insights to inform the co-creation of knowledge.
This initiative leverages the CAMCCO infrastructure, including the CAMCCO-Learning platform, and collaborations with FirstExposure to support knowledge dissemination to target populations.
Dr. Grandi is a co-Investigator on the CIHR Women’s Hub grant and Member of the CAMCCO- Outreach Scientific Advisory Committee.